Translational insights into the underlying pathogenesis of anthracycline-induced cardiotoxicity

niversity of Liverpool0 个研究点目标入组 12 人开始时间: 2020年11月20日最近更新: 2023年12月4日

试验速览

暂无简介。

•Cardiotoxicity cohort:
•1. Over 16 years of age at the time of consent
•2. Capable of providing informed consent as determined by the consenting clinician
•3. Receiving doxorubicin chemotherapy treatment at the time of consent or previously received doxorubicin chemotherapy treatment prior to consent
•4. Clinical presentation of left ventricular systolic dysfunction at the time of consent secondary to receiving doxorubicin chemotherapy treatment as determined by the clinical team
•Non-cardiotoxicity cohort:
•1. Over 16 years of age at the time of consent
•2. Capable of providing informed consent as determined by the consenting clinician
•3. Receiving doxorubicin chemotherapy treatment at the time of consent or previously received doxorubicin chemotherapy treatment prior to consent
•4. Normal left ventricular systolic function at the time of consent secondary to receiving doxorubicin chemotherapy treatment as determined by the clinical team

•1. Under 16 years of age at the time of consent
•2. Lacking ability to provide informed consent as determined by the consenting clinician
•3. Judged to have been coerced to consent as determined by the consenting clinician
•4. Pre-existing left ventricular systolic dysfunction to be reviewed by the clinical team on a case by case basis
•5. Recent surgery (<3 months)
•6. Excessive alcohol consumption (>30 units a week) and/or recreational drug use
•7. Active immunological disease as determined by the clinical team
•8. On current steroid therapy with the exception of corticosteroid inhaler <2 mg/kg
•9. Active or recent (<6 weeks) serious infection at the discretion of the clinical team
•10. Inability to comply with study procedures

发起方

niversity of Liverpool